bluebird bio, Inc. (BLUE) Position Boosted by Strs Ohio
Strs Ohio raised its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 25.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,400 shares of the biotechnology company’s stock after buying an additional 1,500 shares during the period. Strs Ohio’s holdings in bluebird bio were worth $777,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares during the last quarter. Affinity Investment Advisors LLC acquired a new stake in bluebird bio during the second quarter valued at $246,000. First Mercantile Trust Co. boosted its stake in bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 365 shares during the last quarter. Berkeley Capital Partners LLC acquired a new stake in bluebird bio during the first quarter valued at $282,000. Finally, Teacher Retirement System of Texas acquired a new stake in bluebird bio during the first quarter valued at $291,000.
bluebird bio, Inc. (NASDAQ BLUE) opened at 92.45 on Friday. The company’s 50-day moving average price is $96.49 and its 200 day moving average price is $91.07. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75. The company’s market capitalization is $4.21 billion.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $16.70 million during the quarter, compared to analysts’ expectations of $6.29 million. During the same quarter in the prior year, the firm posted ($1.59) earnings per share. bluebird bio’s quarterly revenue was up 977.4% on a year-over-year basis. On average, equities analysts expect that bluebird bio, Inc. will post ($6.78) EPS for the current fiscal year.
Several analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $112.00 price target on shares of bluebird bio in a report on Thursday, June 1st. Zacks Investment Research cut bluebird bio from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $88.00 price target on shares of bluebird bio in a report on Friday, August 11th. Finally, Maxim Group raised bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $100.74.
In other bluebird bio news, insider Philip D. Gregory sold 750 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $99.00, for a total transaction of $74,250.00. Following the sale, the insider now directly owns 31,234 shares in the company, valued at $3,092,166. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James Mandell sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $95.95, for a total value of $95,950.00. Following the sale, the director now owns 1,000 shares in the company, valued at $95,950. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 80,106 shares of company stock worth $8,308,358. Company insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.